echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Facing Omikron, where is the next "special medicine"?

    Facing Omikron, where is the next "special medicine"?

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The COVID-19 outbreak started in early 2020 and has not completely disappear.


    In more than two years, since the first known as "people's hope" Remdesivir, some new crown treatment drugs have appeared in the public eye one after another, but with the continuous mutation and evolution of the new crown virus, it has also made Treatment becomes more complicat.


    0 1 Current status of new crown drug development: racing with mutant strains

    0 1 Current status of new crown drug development: racing with mutant strains

    According to statistics from Guotai Junan Securities, as of March 28, 2022, more than 10 novel coronavirus therapeutic drugs have been approved worldwi.


    Among them, neutralizing antibodies are widely used in Europe and the United States, and the treatment cost is hi.


    However, the most important thing to face is that neutralizing antibodies mainly target the S protein to function, while the mutations generated by the Omicron strain are mainly located in the S protein, and the treatment of neutralizing antibodies can cause esca.


    New crown oral antiviral drugs generally function against viral enzyme structures (RdRp, 3CLpro, PLpro, e.


    Therefore, the small molecule new crown oral drug has become the most promising drug against Omicr.


    From a macro perspective, most of the currently approved neutralizing antibodies, new crown oral drugs and other drugs are mainly aimed at mild patients and prevent the transformation of mild to seve.


    0 2 Reducing the severity and mortality of the new crown, the top priority of prevention and control

    0 2 Reducing the severity and mortality of the new crown, the top priority of prevention and control

    On November 24, 2021, South Africa reported the first case of Omicron variant infection to W.


    Omicron also has a series of sub-variants, of which .


    On the whole, most of the Omicron variant infection cases are asymptomatic or mild cases, and there is a trend towards influenza developme.


    The latest research from the international authoritative medical journal "JAMA" shows that in Massachusetts, the new coronavirus variant Omicron has caused more excess deaths than Del.


    At present, the main epidemic strain in China is the Omicron .


    On May 22, 2022, Professor Zhang Wenhong published the latest research and judgment on China's new crown pneumonia in an academic exchan.


    The report pointed out that vulnerable populations are the biggest challenge since the outbreak of Omicr.


    Since the outbreak of the new crown pneumonia, although there are prevention and control measures such as nucleic acid testing, new crown vaccines, and therapeutic drugs, in the face of the new crown virus that may not disappear in the short term, the task of reducing the severity and mortality of the new crown is expected to remain in the current prevention and contr.


    0 3 AI-assisted screening, some drug candidates emerged

    0 3 AI-assisted screening, some drug candidates emerged

    According to data from authoritative academic institutions, although most COVID-19 patients have only mild to moderate symptoms, 15-20% of patients will still experience excessive inflammation caused by the production of a large number of cytokines, that is, "cytokine storm", which will eventually lead to Alveolar damage and respiratory failu.

    Once a patient develops a cytokine storm, a ventilator is usually requir.

    Solving the cytokine storm in patients is one of the effective means to treat severe new coronary pneumon.

    There are mainly anti-cytokine antibodies or anti-cytokine receptor antibodi.

    There are only a handful of drugs in this pa.

    In cytokine therapy, only Eli Lilly/Incyte's JAK inhibitor Baricitinib and Roche's anti-inflammatory drug Tocilizumab have previously received emergency use authorization from the US FDA, Humanigen's Lenzilumab has submitted an NDA, and Tianjing Bio's Plonmarlimab , Kiniksa's Mavrilimumab and Shutaishen's BDB-001 are in clinical tria.

    On May 11 this year, baricitinib was officially approved by the FDA for the treatment of hospitalized adult patients with COVID-19 receiving supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECM.

    In addition, baricitinib has also been recommended by the World Health Organization (WHO) in the latest update of the new crown treatment guidelines for the treatment of severe patients with pneumonia and hypox.

    In addition, it is worth noting that the team at the Fred Hutchinson Cancer Research Center at the University of Washington has also achieved some cutting-edge research results on the way to find drugs for the treatment of moderate and severe new crow.

    The research team found that the N-terminus of the SARS-CoV-2 spike protein can promote the release of cytokines in immune cel.

    As early as last September, researchers at the Hutchinson Cancer Research Center used AI screening to find that this process is related to JAK1, EPHA7 , IRAK1, MAPK12 and MAP3K8 and other kinases are related, and the multi-kinase inhibitor Ponatinib was further screened to inhibit the occurrence of this inflammatory sto.

    One of the main targets of Ponitinib is Bcr-A.

    Prior to this, there were also related studies on BCR-ABL inhibitors for the treatment of new crown dru.

    For example: In June 2020, Dutch scientists published an article in the preprinted journal BioRxiv and found that the Bcr-Abl inhibitors Imatinib and Ponatinib can bind to RBD with μM-level affinity, providing another explanation for their mechanism of action against the new crown inflammatory storm; In February 2021, Dutch scientists published a review article in the journal Blood Advances on the immune regulation of hematologic tumor kinase inhibitors for COVID-19, pointing out the mechanism and potential therapeutic value of JAK inhibitors and BCR-ABL inhibitors in regulating inflammatory stor.

    Ponatinib is a novel orally active multi-target TKI developed and produced by Takeda Pharmaceuticals, which has previously been approved for chronic myeloid leukem.

    Targets include BCR-ABL, VEGFR, PDGFR, FGFR, EPH, SRC family, KIT, RET, TIE2 and FLT It has been validated in BCR-ABL positive leukem.

    However, public information shows that Takeda Ponatinib was in short supply at that time, and there were no additional doses to conduct clinical trials for the treatment of COVID-1 It's worth noting that Ponatinib was not the only potential drug that Gujral's team screen.

    Not long ago, on May 18, 2022, a preclinical study at the Hutchinson Cancer Research Center showed that Ponatinib's same-target drug orebatinib (Neric®, olverembatinib) can effectively inhibit the new coronavirus variant vir.

    The production of cytokine storm in human peripheral blood mononuclear cells (PBMCs) induced by SARS-CoV-2-Omicron, suggesting that orebatinib has the potential to treat novel coronavirus pneumonia (COVID-19) Especially the potential of moderate to severe patien.

    The study was successfully published in EMBO Molecular Medicine, a top journal of the European Molecular Biology Organizati.

    This study confirmed that SARS-CoV-2-Omicron variant NTD (Omicron-NTD) can also significantly stimulate a variety of cells released in PBM.

    Factors, including IL-1β, IL-6 and tumor necrosis factor (TNF-.

    Compared to baricitinib and ponatinib, orebatinib showed more potent inhibition of Omicron-NTD-mediated cytokine relea.

    Baricitinib itself has obtained dual certification in the treatment of severe new crowns, from emergency authorization to FDA official approval on the one hand, and the latest WHO guidelines on the other ha.

    This has also made the outside world have more expectations for the therapeutic potential of Orebatin.

    Orebatinib is an original class 1 new drug of Ascentage Pharma with global "best-in-class" potential and has been approved for marketing in China for the treatment of chronic myeloid leukemia with T315I mutation and resistance to any TKI (CML) chronic phase (CP) or accelerated phase (AP) adult patients, is the first and only third-generation BCR-ABL inhibitor approved for marketing in Chi.

    The conclusion of this study is only a preclinical study, and the specific efficacy needs to be advanced to clinical tria.

    However, the use of AI to screen drug candidates has reduced the cost of trial and error for pharmaceutical compani.

    Omicron is still raging around the wor.

    If pharmaceutical companies push the already-marketed drugs into clinical trials, they will undoubtedly have a certain advantage over those brand-new drug candidat.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.